New Triple-Threat treatment tested for aggressive blood cancer
NCT ID NCT06514261
Summary
This early-stage trial is testing whether combining three cancer drugs—iadademstat, venetoclax, and azacitidine—is safe and tolerable for adults with newly diagnosed acute myeloid leukemia (AML) who haven't received treatment yet. The study aims to find the best dose of this combination and check for side effects while also looking for early signs that it might help control the cancer. About 45 participants will receive the drug combination in cycles, with close monitoring for safety and how their leukemia responds.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
RECRUITINGOrange, California, 92868, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
SUSPENDEDIrvine, California, 92612, United States
-
University of Cincinnati Cancer Center-UC Medical Center
RECRUITINGCincinnati, Ohio, 45219, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh Cancer Institute (UPCI)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.